251 related articles for article (PubMed ID: 23831947)
21. [OMICS and biomarkers of glial tumors].
Idbaih A
Rev Neurol (Paris); 2011 Oct; 167(10):691-8. PubMed ID: 21889780
[TBL] [Abstract][Full Text] [Related]
22. BRAF inhibitors in BRAF-V600 mutated primary neuroepithelial brain tumors.
Preusser M; Bienkowski M; Birner P
Expert Opin Investig Drugs; 2016; 25(1):7-14. PubMed ID: 26536389
[TBL] [Abstract][Full Text] [Related]
23. Gliomatosis cerebri in children shares molecular characteristics with other pediatric gliomas.
Broniscer A; Chamdine O; Hwang S; Lin T; Pounds S; Onar-Thomas A; Shurtleff S; Allen S; Gajjar A; Northcott P; Orr BA
Acta Neuropathol; 2016 Feb; 131(2):299-307. PubMed ID: 26744350
[TBL] [Abstract][Full Text] [Related]
24. [Histomolecular diagnosis of glial and glioneuronal tumours].
Métais A; Rousseau A
Ann Pathol; 2021 Apr; 41(2):137-153. PubMed ID: 33712303
[TBL] [Abstract][Full Text] [Related]
25. Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management.
Taylor JW; Chi AS; Cahill DP
Oncology (Williston Park); 2013 Jun; 27(6):504-14. PubMed ID: 23909061
[TBL] [Abstract][Full Text] [Related]
26. Molecular classification defines 4 prognostically distinct glioma groups irrespective of diagnosis and grade.
Mur P; Mollejo M; Hernández-Iglesias T; de Lope ÁR; Castresana JS; García JF; Fiaño C; Ribalta T; Rey JA; Meléndez B
J Neuropathol Exp Neurol; 2015 Mar; 74(3):241-9. PubMed ID: 25668564
[TBL] [Abstract][Full Text] [Related]
27. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
[TBL] [Abstract][Full Text] [Related]
28. Molecular subtypes of glioma identified by genome-wide methylation profiling.
Kloosterhof NK; de Rooi JJ; Kros M; Eilers PH; Sillevis Smitt PA; van den Bent MJ; French PJ
Genes Chromosomes Cancer; 2013 Jul; 52(7):665-74. PubMed ID: 23629961
[TBL] [Abstract][Full Text] [Related]
29. Clinical relevance of BRAF status in glial and glioneuronal tumors: A systematic review.
Sugiura Y; Nagaishi M
J Clin Neurosci; 2019 Aug; 66():196-201. PubMed ID: 31147232
[TBL] [Abstract][Full Text] [Related]
30. Integrated molecular analysis suggests a three-class model for low-grade gliomas: a proof-of-concept study.
Marko NF; Prayson RA; Barnett GH; Weil RJ
Genomics; 2010 Jan; 95(1):16-24. PubMed ID: 19835948
[TBL] [Abstract][Full Text] [Related]
31. Gliosis versus glioma?: don't grade until you know.
Rivera-Zengotita M; Yachnis AT
Adv Anat Pathol; 2012 Jul; 19(4):239-49. PubMed ID: 22692287
[TBL] [Abstract][Full Text] [Related]
32. Input of molecular analysis in medical management of primary brain tumor patients.
Idbaih A; Duran-Peña A; Bonnet C; Ducray F
Rev Neurol (Paris); 2015; 171(6-7):457-65. PubMed ID: 26026669
[TBL] [Abstract][Full Text] [Related]
33. Application of multiplex ligation-dependent probe amplification (MLPA) and low pass whole genome sequencing (LP-WGS) to the classification / characterisation of low grade glioneuronal tumours.
Dyke J; Calapre L; Beasley A; Gray E; Allcock R; Bentel J
Pathol Res Pract; 2022 Jan; 229():153724. PubMed ID: 34942511
[TBL] [Abstract][Full Text] [Related]
34. Whole genome analysis from microdissected tissue revealed adult supratentorial grade II-III gliomas are divided into clinically relevant subgroups by genetic profile.
Hirose Y; Sasaki H; Miwa T; Ohba S; Ikeda E; Abe M; Ikeda S; Kobayashi M; Kawase T; Hasegawa M; Yoshida K
Neurosurgery; 2011 Aug; 69(2):376-90. PubMed ID: 21358357
[TBL] [Abstract][Full Text] [Related]
35. Characterization of gliomas: from morphology to molecules.
Ferris SP; Hofmann JW; Solomon DA; Perry A
Virchows Arch; 2017 Aug; 471(2):257-269. PubMed ID: 28674742
[TBL] [Abstract][Full Text] [Related]
36. Alterations of the TP53 gene in human gliomas.
Rasheed BK; McLendon RE; Herndon JE; Friedman HS; Friedman AH; Bigner DD; Bigner SH
Cancer Res; 1994 Mar; 54(5):1324-30. PubMed ID: 8118823
[TBL] [Abstract][Full Text] [Related]
37. EANO - EURACAN - SNO Guidelines on circumscribed astrocytic gliomas, glioneuronal, and neuronal tumors.
Rudà R; Capper D; Waldman AD; Pallud J; Minniti G; Kaley TJ; Bouffet E; Tabatabai G; Aronica E; Jakola AS; Pfister SM; Schiff D; Lassman AB; Solomon DA; Soffietti R; Weller M; Preusser M; Idbaih A; Wen PY; van den Bent MJ
Neuro Oncol; 2022 Dec; 24(12):2015-2034. PubMed ID: 35908833
[TBL] [Abstract][Full Text] [Related]
38. An integrative molecular and genomic analysis of pediatric hemispheric low-grade gliomas: an update.
Lassaletta A; Zapotocky M; Bouffet E; Hawkins C; Tabori U
Childs Nerv Syst; 2016 Oct; 32(10):1789-97. PubMed ID: 27659822
[TBL] [Abstract][Full Text] [Related]
39. BRAF V600E mutations are frequent in dysembryoplastic neuroepithelial tumors and subependymal giant cell astrocytomas.
Lee D; Cho YH; Kang SY; Yoon N; Sung CO; Suh YL
J Surg Oncol; 2015 Mar; 111(3):359-64. PubMed ID: 25346165
[TBL] [Abstract][Full Text] [Related]
40. Clinical-pathological study of 28 glial and mixed neuronal-glial tumors diagnosed within the first year of life.
Buccoliero AM; Caporalini C; Moscardi S; Spacca B; Scagnet M; Castiglione F; Sardi I; Giunti L; Genitori L
Clin Neuropathol; 2022; 41(1):25-34. PubMed ID: 34622774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
